Arlet

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arlet

Property Description
Active Ingredient Amoxicillin and Clavulanic acid
Common Forms Tablets, oral suspension
Pharmacological Class beta-Lactam antibiotic, beta-Lactamase Inhibitor combination
General Purpose Treatment of bacterial infections
Origin Semi-synthetic and Naturally derived

Arlet is defined as a specialized antibacterial drug and a fixed-dose combination drug consisting of two essential components: the aminopenicillin antibiotic Amoxicillin and the protecting agent Clavulanic acid. Its formulation is often recognized by the generic descriptor Co-amoxiclav. The combination is clinically recognized for its ability to eliminate common bacterial infections, such as those affecting the respiratory tract or the skin.

The formulation is classified within the pharmaceutical hierarchy as a beta-Lactam antibiotic and beta-Lactamase Inhibitor combination. The Amoxicillin component is semi-synthetic, while Clavulanic acid is naturally derived from fermentation processes. The combination is particularly effective against infections where the causative bacteria have developed resistance, establishing the compound's recognized expertise in complex drug development.

Forms, Structure, and General Therapeutic Purpose

This medicine is available in several pharmaceutical preparations, including film-coated tablets and powder for oral suspension, allowing for flexible and effective delivery across different patient groups. The fundamental purpose of this structural pairing is to utilize a synergistic effect against bacteria.

The unique structure is predicated on the synergistic action of its two components: Amoxicillin provides the bactericidal action by damaging the bacterial cell wall, while the Clavulanic acid inhibitor neutralizes the protective enzymes that some bacteria use to resist standard penicillins. This mechanism ensures that the antibiotic is protected and its therapeutic reach is extended to effectively eliminate bacterial infections.

What side effects are possible with Arlet?

Possible Side Effects and Safety Information

The safety profile for Arlet (Apalutamide) is officially characterized by adverse reactions classified by frequency and System-Organ Class. These classifications provide a regulatory-based understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions (Selected)

System-Organ Class (SOC) Frequency Category Listed Adverse Reactions (Examples)
General Disorders Very Common (affecting ge 1 in 10 people) Fatigue, Hot flush, Fall
Vascular Disorders Very Common Hypertension (High blood pressure)
Skin Disorders Very Common Rash
Musculoskeletal Disorders Very Common Arthralgia (Joint pain), Fracture
Nervous System Disorders Uncommon (affecting ge 1 in 1,000 to < 1 in 100 people) Seizure

Serious Adverse Reactions and High-Risk Events

Official documents highlight certain serious adverse reactions. These include seizure, ischemic cardiovascular events (such as heart attack or stroke), and severe skin reactions known as Severe Cutaneous Adverse Reactions (SCARs), which encompass Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Cases of Interstitial Lung Disease (ILD)/Pneumonitis have also been reported. The label notes that rash often manifests early in the course of treatment.

Population-Specific Safety Constraints

The medicine is contraindicated in women who are or may become pregnant. Men with female partners of reproductive potential are required to use effective contraception during and for a specified period after treatment, and must not donate sperm. The incidence of falls and fractures is documented to occur more frequently in older adults. Furthermore, the medicine is not recommended in patients with a history of seizure or predisposing factors, and caution is advised in those with severe hepatic impairment due to lack of data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Arlet (Apalutamide) addresses suspected overdose by outlining mandatory emergency procedures rather than defining a specific set of acute symptoms. No distinct clinical signs or specific physiological manifestations of overdose are formally documented in the prescribing information.

Should an overdose be suspected, immediate medical attention is required. The first mandated action by regulatory authorities is the immediate discontinuation of the medicine. The official label explicitly states that there is no known specific antidote available to reverse the drug’s effects. This constraint makes procedural management and supportive care the central requirement.

Management is strictly defined as symptomatic and supportive treatment, mandating that general supportive measures must be undertaken. These measures must be maintained, and the patient must remain under continuous clinical observation, until any resulting clinical toxicity has been diminished or completely resolved. This requirement necessitates close monitoring, which aligns with official regulatory instructions. The official documentation does not provide specific differing instructions or separate considerations for managing overdose in populations with hepatic or renal impairment, focusing instead on the universal management strategy.

Therapeutic Uses of Arlet

Quick Facts: What Arlet Supports

  • Treatment Area: Hormone-sensitive and castration-resistant prostate cancer.
  • Main Goal: May help manage specific forms of prostate cancer in adult men.
  • Therapeutic Role: May be used in combination with androgen deprivation therapy (ADT) or as a single agent in certain settings.

Arlet (Apalutamide) is an authorized medicinal product for therapeutic use in adult men with prostate cancer. The primary applications involve two specific clinical situations.

Firstly, Arlet is indicated for the management of non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who have a high potential for the disease to spread. In this context, the medication is intended to support the established treatment plan.

Secondly, the medication is used for treating metastatic hormone-sensitive prostate cancer (mHSPC). For this indication, Arlet is administered alongside standard androgen deprivation therapy to offer comprehensive support for the condition. The goal of therapy is to assist in the sustained management of the disease and related outcomes.

This medication is a prescription product, and its use should be overseen by a medical specialist with expertise in the care and treatment of prostate cancer. Consulting with a healthcare provider is essential for understanding individual treatment goals.

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

The eligibility profile for Arlet (Apalutamide) is defined by official regulatory criteria that specify who is permitted to use the medicine and who is prohibited.

Eligibility Scope Official Regulatory Statement
Populations for whom use is allowed Adult men are the established patient population for treatment of prostate cancer.
Populations for whom use is not recommended Use is not recommended in patients with severe hepatic impairment (Child-Pugh C), as the drug's effects are unestablished in this population.
Populations for whom use is contraindicated The medicine is contraindicated in women who are or may become pregnant due to the risk of fetal harm. It is also contraindicated in patients with a known hypersensitivity to the drug or its excipients.
Age-related eligibility rules The medication is not indicated for the pediatric population. For older adults, studies have not demonstrated geriatric-specific issues that would restrict use.
Condition-specific eligibility rules Caution is required when prescribing to patients with severe renal impairment. Patients with a history of seizure or recent significant cardiovascular events were excluded from primary clinical trials, meaning safety has not been established in these groups.
Pregnancy and lactation eligibility status Pregnancy is a strict contraindication. Safety and efficacy have not been established in the female population; therefore, use during lactation is not indicated.
Eligibility-related restrictions Males with female partners of reproductive potential must use effective contraception during treatment and for three months following the last dose.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated for women who are or may become pregnant and for patients with known hypersensitivity.
  • Use is established only in adult men with prostate cancer; it is not indicated for children or adolescents.
  • Use is not recommended in severe hepatic impairment and requires caution in severe renal impairment.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define who can and cannot use the medicine by establishing adult men as the primary use population and setting strict absolute contraindications based on sex and hypersensitivity. Eligibility is further restricted by conditional use requirements for patients with severe organ impairment and prior health conditions (like a history of seizure) where clinical trial data is insufficient.

What should I know about interactions with other medicines?

Arlet's official interaction profile is defined by its pharmacokinetic effect as a potent inducer of multiple metabolic enzymes and drug transporters. The regulatory documentation states that the medication is a strong inducer of the CYP3A4 and CYP2C19 enzymes, as well as a weak inducer of P-glycoprotein (P-gp), BCRP, and UGT enzymes. This extensive induction can result in a substantial reduction of systemic exposure for sensitive co-administered medications that are substrates for these pathways, an effect detailed in the prescribing information.

Interaction Type Interacting Substance/Class Official Regulatory Statement
Exposure Decrease Substrates of CYP3A4, CYP2C19, P-gp (e.g., Digoxin, Simvastatin) Co-administration results in reduced plasma concentration of the substrate.
Exposure Increase Strong CYP2C8 Inhibitors (e.g., Gemfibrozil) Systemic exposure of Apalutamide is increased.
Mandatory Monitoring Warfarin and Coumarin-like Anticoagulants Combination should be avoided; if necessary, additional INR monitoring is required due to CYP2C9 induction.
Population-Specific Severe Hepatic Impairment (Child-Pugh C) Close monitoring of liver function is recommended as the pharmacokinetic effect is unknown.

Medications which lower the seizure threshold or prolong the QT interval are noted to require careful evaluation. Furthermore, no administration timing separation is required for co-administered medications, and no clinically significant food interaction has been confirmed.

Mechanism of Action

How Arlet Works: Mechanistic Domains

The effect of Arlet (Amoxicillin and Clavulanic acid) stems from a synergistic two-part mechanism that first neutralizes bacterial defenses and then applies a defined action on the bacterial structure.


Direct Bactericidal Mechanism: Targeting Cell Wall Integrity

This domain involves Amoxicillin, which acts as an irreversible covalent inhibitor of Penicillin-Binding Proteins (PBPs)—essential enzymes used by bacteria to construct their cell wall. By blocking the final transpeptidation step, the drug disrupts the cell wall's rigid structure. This results in the loss of structural integrity, leading to uncontrolled osmotic pressure, activation of bacterial autolytic enzymes, and rapid bacterial cell lysis, resulting in a bactericidal physiological effect.


️ Resistance Neutralization: Protecting the Mechanism

This synergistic domain involves Clavulanic acid, which functions as a mechanism-based irreversible inhibitor of specific bacterial beta-lactamase enzymes. These enzymes typically destroy the antibiotic before it can reach the PBPs. By acting as a decoy substrate, Clavulanic acid permanently inactivates the beta-lactamases. This protection permits the core bactericidal action to occur against organisms possessing enzymatic defenses. This mechanism restores the functional efficacy of Amoxicillin, allowing the core bactericidal action to proceed.

Dosage and Administration Information

Arlet (Apalutamide) is administered exclusively through the oral route as part of a continuous, non-cyclic regimen. The standard labeled dose is 240 mg, which is taken once daily. This dose is typically achieved by taking four 60 mg film-coated tablets or one 240 mg tablet. The frequency of use is daily, and it may be taken with or without food.

The medicine must be used in conjunction with continuous hormone therapy; patients are required to receive a concurrent gonadotropin-releasing hormone (GnRH) analog or have undergone a prior bilateral orchiectomy. This co-therapy requirement is integral to the product’s official usage protocol.

For administration, the tablets should be swallowed whole and must not be crushed, split, or chewed, as this compromises the intended dosage delivery. If a patient is unable to swallow whole tablets, the dose can be prepared by dispersing it in non-carbonated water and mixed with certain liquids; any such mixture must be consumed immediately and not stored.

Regarding the maintenance of the schedule, if a dose is missed, it should be taken as soon as it is remembered on the same day. However, if an entire day is missed, the patient should skip the missed dose and return to the normal schedule the following day, never taking two doses at once. Dose reductions, such as to 180 mg or 120 mg, are explicitly defined in the label to manage administration-related issues, and they are not initial treatment options. No dose adjustments are initially required for patients with mild or moderate kidney or liver impairment, though the medicine is not recommended for use in severe hepatic impairment.

Recent Clinical Evidence

The term Arlet primarily refers to the Ficat and Arlet classification system, which is a widely used clinical and radiographic staging method for avascular necrosis (AVN) of the femoral head (hip joint). This system assesses the progression of the disease, which is the death of bone tissue due to a lack of blood supply, helping to guide treatment decisions.

While Arlet is not a drug, the clinical management strategies for AVN, particularly in the early stages defined by the Arlet classification (Stages I and II), are frequently the subject of recent clinical investigations. Treatment evidence focuses on delaying disease progression and preserving the joint. Current research areas include:

  • Pharmacological Interventions: Studies continue to investigate the role of various medications in conservative management. Bisphosphonates, which help prevent bone density loss, are often evaluated for their ability to halt the progression from early-stage AVN (Arlet Stages I and II) to collapse (Stages III and IV).
  • Risk Factor Modification: Clinical evidence consistently supports the importance of addressing modifiable risk factors, such as discontinuing corticosteroid use where possible, managing associated hyperlipidemia (high cholesterol), and eliminating excessive alcohol consumption. These lifestyle and medication adjustments are integral to early-stage treatment protocols.
Arlet Stage Clinical Focus of Recent Research
Stage I-II Preventing joint collapse; efficacy of bisphosphonates; pain management.
Stage III-IV Surgical strategies; optimization of total joint replacement outcomes.

For advanced stages (Arlet Stages III and IV) where joint collapse has occurred, the clinical evidence confirms that total hip replacement remains the definitive standard of care, with ongoing studies focused on refining surgical techniques and implant longevity.

Key Studies & References

  1. Osteonecrosis of The Femoral Head Based on The Ficat and Arlet Classification: A Literature Review
  2. Hip Osteonecrosis - Recon - Orthobullets (Referencing Ficat and Arlet Staging and Conservative Management)
  3. Evidence for Using Alendronate to Treat Adult Avascular Necrosis of the Femoral Head: A Systematic Review
  4. Avascular Necrosis of the Hip | Fact Sheets - Yale Medicine (Overview of Risk Factors and Treatment Strategies)

Frequently Asked Questions (FAQ)

Common questions about Arlet (FAQ)


Q: What types of foods or drinks should be mentioned to a doctor when discussing Arlet?

Official documents state that Arlet can be taken with or without food. However, it is standard practice for healthcare professionals to review a patient's use of the medicine alongside their diet, including any consumption of alcohol or tobacco. This review helps ensure that all potential non-critical factors are considered.

Q: Is it true that Arlet can interact with some common over-the-counter medications?

Regulatory documents note that this medicine is a strong inducer of several liver enzymes, such as CYP3A4, which are responsible for processing many other drugs. This effect may lead to a lower concentration of co-administered medications that are processed by these enzymes, which can include some over-the-counter products.

Q: Does Arlet require any special tests or monitoring while a person is using it?

Official guidelines recommend monitoring for potential risks such as signs of heart disease, fractures, and fall risk. Your healthcare professional may also use blood tests to check for certain side effects, such as abnormal levels of cholesterol or other substances.

Q: Is Arlet considered a high-risk medication by regulatory bodies?

Regulatory bodies provide detailed information on all known risks, which includes a specific section detailing Warnings and Precautions for serious adverse reactions. These reactions include seizures, severe skin reactions, fractures, and cardiovascular events, which are continuously monitored and reviewed.

Q: What is the difference between how Arlet works and how other related drugs work?

The medicine works primarily as a highly potent androgen receptor inhibitor. The mechanism focuses on blocking the effects of male hormones. The specific functional differences compared to other similar drugs would require a direct clinical comparison, which is not provided in the medicine’s official regulatory labeling.

Q: Is Arlet something people use short-term or long-term?

For its approved use in prostate cancer, the medicine is prescribed as a continuous, once-daily regimen. The duration of use is decided by the patient's prescribing physician based on the individual treatment plan.

Q: Do studies suggest Arlet is more or less effective depending on age or gender?

Official studies for this medicine focused only on adult men, who are the indicated patient population. Regulatory data indicates that certain adverse events, like falls and fractures, occurred more frequently in elderly patients, though studies have not demonstrated specific issues that restrict use in older adults.

Q: What is a 'contraindication' for Arlet, explained simply?

A contraindication is the term used in medicine to describe a condition or circumstance that makes treatment with a specific drug improper or potentially harmful. This medicine should not be used by women who are or may become pregnant or by patients who have a known allergy (hypersensitivity) to the drug.

Q: Can Arlet cause problems with sleep?

Official regulatory labeling generally does not list sleep disturbances like insomnia as a common side effect. Some patient-focused information suggests that adjustments to the timing of administration may be discussed with a doctor if sleep disturbances occur.

Q: Are there any known issues with taking Arlet and vitamins or supplements?

The medicine can affect certain protein transporters, such as P-glycoprotein, which are used by the body to move various substances. Because many vitamins and supplements use these same pathways, the use of these substances may result in lower exposure for the supplement.

Q: What is the safety class or category of Arlet?

The official documents classify this medicine as strictly contraindicated for use in women who are or may become pregnant due to the risk of fetal harm. It is also not classified as a controlled substance under the DEA schedule.

Q: Does Arlet have a generic version available?

The drug Apalutamide is the active ingredient in Arlet. Currently, Apalutamide is not available in a generic (non-brand) form.

Q: Do any official documents describe Arlet as being habit-forming?

No, the medicine is not classified as a controlled substance by regulatory bodies like the DEA. The official product documentation does not describe the drug as being habit-forming or having the potential for dependence.

Q: What happens if someone stops using Arlet suddenly?

Regulatory information focuses on stopping or temporarily holding the drug primarily due to severe side effects or if the disease progresses. The official drug label does not provide information regarding specific withdrawal symptoms or discontinuation syndrome when the medicine is stopped.

Q: Are there warnings about Arlet and driving or operating machinery?

Yes, regulatory warnings caution patients regarding driving a car or operating machinery until they know how the medication affects them. This caution is advised due to the risk of seizures and potential dizziness listed in the official safety profile.

Q: Is it described anywhere that Arlet might cause weight changes?

Yes, according to official adverse reaction reports, both a decrease in weight (weight loss) and weight gain are listed as reported side effects associated with the medicine.

Q: What should be done if a user notices a very rare side effect mentioned in the leaflet?

The official patient information advises that any side effect that is bothersome or does not go away should be reported to a healthcare professional.

Q: Are headaches a commonly reported experience when taking Arlet?

Headaches have been reported as a side effect in regulatory documents. The frequency of headaches can vary between clinical studies, but they are recognized as a possible reaction.

Q: Does taking Arlet affect the results of any common lab tests?

Yes, the medicine can affect certain blood test results. Official adverse reaction reporting specifically notes that this medicine can cause abnormal blood levels of substances such as cholesterol, triglycerides, potassium, and thyroid-stimulating hormone (TSH).

Q: Are there any known long-term side effects that regulatory bodies are monitoring for Arlet?

Regulatory bodies continuously monitor all reported adverse events associated with a medicine. This long-term monitoring is particularly focused on reactions categorized in the Warnings and Precautions sections, such as cardiovascular events and fractures.

Q: What is the most common reason people stop taking Arlet?

Clinical trial data indicates that the most common reason patients stopped taking the medicine was due to adverse events (side effects). This information is recorded and reviewed by regulatory agencies.

Q: How does Arlet's half-life relate to how often it is usually taken?

Studies have examined the medicine's behavior in the body. The half-life of Apalutamide is approximately 3 days at steady state, which is the amount of time it takes for half of the drug to be eliminated. This long half-life supports the once-daily dosing regimen.

Q: Are there specific symptoms that require immediate medical attention while using Arlet?

Yes, the official labeling highlights that immediate medical attention should be sought for symptoms of a severe adverse reaction, such as a severe rash, seizures, or signs of a heart attack or stroke.

How should Arlet be stored and disposed of?

How to Store and Dispose of Arlet (Apalutamide)

Official regulatory guidelines dictate specific conditions for storing and disposing of Arlet tablets to maintain stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F); keep from freezing.
Protection Store in the original container, protected from light and moisture.
Child Safety Must be kept out of the sight and reach of children.
Mixture Stability If the tablet is mixed with liquid, it must be swallowed immediately and not stored for later use.

Disposal Instructions

Unused or expired Arlet must be disposed of through a drug take-back program or returned to a pharmacy. The medication must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arlet found in:

A-Z Index: